Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-241-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110216.11.3-241-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"−
I voted in favour of the legislative motion for a resolution of the European Parliament on the proposal for a directive of the European Parliament and of the Council amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of medicinal products which are falsified in relation to their identity, history or source. There can be no doubt that the appearance of falsified medicines in official distribution channels represents a threat to the entire European pharmaceutical system, by undermining the trust of citizens in the quality of drugs purchased in pharmacies or other legal outlets.
In my opinion, the most disturbing aspect is the change in the risk profile. To date, counterfeit products have mainly come under the heading of ‘life-style’ drugs, whereas there is currently a dramatic increase in the number of counterfeit life-saving medicines. It is therefore important to establish a clear and unambiguous definition of a ‘falsified medicinal product’. but also to define all the entities in the distribution chain, such as sellers and agents who must operate on the basis of permits and abide by the rules of good manufacturing practices, as do the manufacturers and distributors. In view of the above, I consider that it is necessary and a matter of priority to support any measures aimed at minimising this problem."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples